Two-Antibody Cocktail Developed to Combat Drug-Resistant RSV

Chinese scientists have developed a two-antibody cocktail to treat respiratory syncytial virus (RSV) that prevented drug resistance in laboratory studies, addressing a persistent challenge in treating infants with current therapies. RSV is a seasonal infection that circulates globally and poses particular danger to infants and older adults. While pharmaceutical companies including GlaxoSmithKline, Pfizer, and Moderna have developed vaccines for people 65 and older—Arexvy, ABRYSVO, and mRESVIA respectively—no RSV vaccine exists for infants, who remain among the most vulnerable populations. The dual-antibody approach represents a potential breakthrough for protecting this high-risk infant population.

Development of two-antibody cocktail for drug-resistant RSV

• ▪Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus (RSV)
• ▪Drug resistance is a persistent problem with current therapies for respiratory syncytial virus (RSV) in infants
• ▪The two-antibody cocktail developed by scientists in China prevented respiratory syncytial virus (RSV) from developing drug resistance in laboratory studies

RSV vulnerability across age groups and current vaccine availability

• ▪There is no available respiratory syncytial virus (RSV) vaccine for infants
• ▪Respiratory syncytial virus (RSV) is a seasonal infection that circulates globally
• ▪Respiratory syncytial virus (RSV) can be especially dangerous for infants and older adults
• ▪GlaxoSmithKline's Arexvy is a respiratory syncytial virus (RSV) vaccine available for people who are 65 and older
• ▪Infants are among the most vulnerable to respiratory syncytial virus (RSV)

Perspective of Chinese scientists who developed the two-antibody cocktail

• ▪The two-antibody cocktail approach addresses drug resistance issues that have limited the effectiveness of single-antibody respiratory syncytial virus (RSV) treatments

Perspective of Pharmaceutical companies with existing RSV vaccines

• ▪Current respiratory syncytial virus (RSV) vaccine manufacturers have successfully brought products to market for adults aged 65 and older but not for infants